UK backs Opdivo for lung cancer after Bristol-Myers cuts price
LONDON (Reuters) - Bristol-Myers Squibb's immunotherapy drug Opdivo has been recommended for some patients with lung cancer by Britain's healthcare cost watchdog NICE after the drugmaker agreed a discounted price.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
More News: Cancer | Cancer & Oncology | Health | Immunotherapy | Lung Cancer | National Institute for Health and Clinical Excelle | UK Health